Browse by "Oncoloxía médica"

A Phase II Trial of Erlotinib as Maintenance Treatment After Concurrent Chemo-radiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC) - a Galician Lung Cancer Group (GGCP) Study

2011- Afonso Afonso, Francisco Javier; Firvida Perez, Jose Luis; Vázquez Estévez, Sergio; Barón Duarte, Francisco Javier

A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer Group (GGCP) study

2013- Afonso Afonso, Francisco Javier; Lazaro Quintela, Martín; Vázquez Estévez, Sergio; Campos Balea, Begoña; Barón Duarte, Francisco Javier; [et al.]

A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer Group (GGCP) study.

2014- Firvida Perez, Jose Luis; Vázquez Estévez, Sergio; Campos Balea, Begoña; Barón Duarte, Francisco Javier; Alonso-Jaudenes Curbera, Guillermo [et al.]

A phase II, multicenter, four-cohort study of oral cMET inhibitor capmatinib (INC280) in patients with EGFR wild-type, advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease

2015- García Campelo, María del Rosario

A phase II, open-label, neoadjuvant, randomized study of LCL161 with paclitaxel in patients with triple-negative breast cancer (TNBC)

2015- López López, Rafael

A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens

2011- Valladares Ayerbes, Manuel

A primary signet ring cell carcinoma of the prostate with bone metastasis with impressive response to FOLFOX and cetuximab

2012- Antón Aparicio, Luis Miguel; Fernández Nuñez, Natalia; Roldán Corrales, Ana Milena; Alvarez García, Augusto

A randomised phase III intergroup trial comparing high-dose infusional 5-fluorouracil with or without folinic acid with standard bolus 5-fluorouracil/folinic acid in the adjuvant treatment of stage III colon cancer: The Pan-European Trial in Adjuvant Colo

2013- Valladares Ayerbes, Manuel

A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143)

2011- Valladares Ayerbes, Manuel

A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study

2012- Calvo Martínez, Lourdes

A Spanish Cost-utility Analysis of Nab-paclitaxel Compared to Conventional Paclitaxel Monotherapy for Pretreated Metastatic Breast Cancer: Results From the COSTABRAX Study

2012- López López, Rafael

A Three-Gene panel on urine increases PSA specificity in the detection of prostate cancer

2011- Abal Posada, Miguel

Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry

2014- Abdulkader Nallib, Ihab; García Campelo, María del Rosario

Adenocarcinoma de ciego en paciente con situs inversus totalis.

2011- Abal Arca, José; Anido Herranz, Urbano; González Quintela, Arturo; Pazos González, Gerardo

Adherence to capecitabine in patients with colorectal or gastric cancer using microelectronic monitoring systems

2015- Candamio Folgar, Sonia; López López, Rafael; Bernárdez Ferrán, Beatriz; Durán Piñeiro, Goretti; Lamas Díaz, María Jesús; [et al.]

Adjuvant chemoradiotherapy with infusional fluorouracil in high-risk adenocarcinoma of the stomach or gastroesophageal junction

2014- Vieito Villar, María; Candamio Folgar, Sonia; López López, Rafael; Vidal Insua, Yolanda; Vázquez Rivera, Francisca; [et al.]

Adjuvant regimens with trastuzumab administered for small HER2-positive breast cancer in routine clinical practice

2015- Antolín Novoa, Silvia

ADJUVANT TREATMENT USED WITH TRASTUZUMAB IN BREAST CANCER WITH <= 1.5 cm TUMOR SIZE PATIENTS

2013- Antolín Novoa, Silvia

Adjuvant treatment with infusional 5-fluorouracil in high risk adenocarcinoma of the stomach or gastroesophageal junction

2015- Vieito Villar, María; Candamio Folgar, Sonia; López López, Rafael; Vidal Insua, Yolanda; Vázquez Rivera, Francisca; [et al.]

Adrenal carcinoma: a retrospective analysis of our series

2013- Cameselle Teijeiro, Jose Manuel; Bernabeu Morón, Ignacio; Andujar Plata, Paula; Casanueva Freijo, Felipe; Cabezas Agrícola, José Manuel; [et al.]

RUNA digital repository

Browse by "Oncoloxía médica"

A Phase II Trial of Erlotinib as Maintenance Treatment After Concurrent Chemo-radiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC) - a Galician Lung Cancer Group (GGCP) Study ﻿

A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer Group (GGCP) study ﻿

A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer Group (GGCP) study. ﻿

A phase II, multicenter, four-cohort study of oral cMET inhibitor capmatinib (INC280) in patients with EGFR wild-type, advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease ﻿

A phase II, open-label, neoadjuvant, randomized study of LCL161 with paclitaxel in patients with triple-negative breast cancer (TNBC) ﻿

A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens ﻿

A primary signet ring cell carcinoma of the prostate with bone metastasis with impressive response to FOLFOX and cetuximab ﻿

A randomised phase III intergroup trial comparing high-dose infusional 5-fluorouracil with or without folinic acid with standard bolus 5-fluorouracil/folinic acid in the adjuvant treatment of stage III colon cancer: The Pan-European Trial in Adjuvant Colo ﻿

A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143) ﻿

A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study ﻿

A Spanish Cost-utility Analysis of Nab-paclitaxel Compared to Conventional Paclitaxel Monotherapy for Pretreated Metastatic Breast Cancer: Results From the COSTABRAX Study ﻿

A Three-Gene panel on urine increases PSA specificity in the detection of prostate cancer ﻿

Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry ﻿

Adenocarcinoma de ciego en paciente con situs inversus totalis. ﻿

Adherence to capecitabine in patients with colorectal or gastric cancer using microelectronic monitoring systems ﻿

Adjuvant chemoradiotherapy with infusional fluorouracil in high-risk adenocarcinoma of the stomach or gastroesophageal junction ﻿

Adjuvant regimens with trastuzumab administered for small HER2-positive breast cancer in routine clinical practice ﻿

ADJUVANT TREATMENT USED WITH TRASTUZUMAB IN BREAST CANCER WITH <= 1.5 cm TUMOR SIZE PATIENTS ﻿

Adjuvant treatment with infusional 5-fluorouracil in high risk adenocarcinoma of the stomach or gastroesophageal junction ﻿

Adrenal carcinoma: a retrospective analysis of our series ﻿

A Phase II Trial of Erlotinib as Maintenance Treatment After Concurrent Chemo-radiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC) - a Galician Lung Cancer Group (GGCP) Study

A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer Group (GGCP) study

A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer Group (GGCP) study.

A phase II, multicenter, four-cohort study of oral cMET inhibitor capmatinib (INC280) in patients with EGFR wild-type, advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease

A phase II, open-label, neoadjuvant, randomized study of LCL161 with paclitaxel in patients with triple-negative breast cancer (TNBC)

A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens

A primary signet ring cell carcinoma of the prostate with bone metastasis with impressive response to FOLFOX and cetuximab

A randomised phase III intergroup trial comparing high-dose infusional 5-fluorouracil with or without folinic acid with standard bolus 5-fluorouracil/folinic acid in the adjuvant treatment of stage III colon cancer: The Pan-European Trial in Adjuvant Colo

A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143)

A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study

A Spanish Cost-utility Analysis of Nab-paclitaxel Compared to Conventional Paclitaxel Monotherapy for Pretreated Metastatic Breast Cancer: Results From the COSTABRAX Study

A Three-Gene panel on urine increases PSA specificity in the detection of prostate cancer

Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry

Adenocarcinoma de ciego en paciente con situs inversus totalis.

Adherence to capecitabine in patients with colorectal or gastric cancer using microelectronic monitoring systems

Adjuvant chemoradiotherapy with infusional fluorouracil in high-risk adenocarcinoma of the stomach or gastroesophageal junction

Adjuvant regimens with trastuzumab administered for small HER2-positive breast cancer in routine clinical practice

ADJUVANT TREATMENT USED WITH TRASTUZUMAB IN BREAST CANCER WITH <= 1.5 cm TUMOR SIZE PATIENTS

Adjuvant treatment with infusional 5-fluorouracil in high risk adenocarcinoma of the stomach or gastroesophageal junction

Adrenal carcinoma: a retrospective analysis of our series